减毒天花疫苗LC16m8在免疫缺陷小鼠中的安全性
Safety of attenuated smallpox vaccine LC16m8 in immunodeficient mice.
作者信息
Yokote Hiroyuki, Shinmura Yasuhiko, Kanehara Tomomi, Maruno Shinichi, Kuranaga Masahiko, Matsui Hajime, Hashizume So
机构信息
The Chemo-Sero-Therapeutic Research Institute (Kaketsuken), Okubo, Kita-ku Kumamoto-shi, Kumamoto, Japan
The Chemo-Sero-Therapeutic Research Institute (Kaketsuken), Okubo, Kita-ku Kumamoto-shi, Kumamoto, Japan.
出版信息
Clin Vaccine Immunol. 2014 Sep;21(9):1261-6. doi: 10.1128/CVI.00199-14. Epub 2014 Jul 2.
Abstract
Freeze-dried live attenuated smallpox vaccine LC16m8 prepared in cell culture has been the sole smallpox vaccine licensed in Japan since 1975 and was recently recommended as a WHO stockpile vaccine. We evaluated the safety of recently remanufactured lots of LC16m8 using a series of immunodeficient mouse models. These models included suckling mice, severe combined immunodeficiency disease (SCID) mice, and wild-type mice treated with cyclosporine. LC16m8 showed extremely low virulence in each of the three mouse models compared with that of its parental strains, Lister and LC16mO. These results provide further evidence that LC16m8 is one of the safest replication-competent smallpox vaccines in the world and may be considered for use in immunodeficient patients.
摘要
自1975年以来，在细胞培养中制备的冻干减毒活天花疫苗LC16m8一直是日本唯一获得许可的天花疫苗，最近被推荐作为世界卫生组织的储备疫苗。我们使用一系列免疫缺陷小鼠模型评估了最近重新生产的批次的LC16m8的安全性。这些模型包括乳鼠、严重联合免疫缺陷病（SCID）小鼠和用环孢素处理的野生型小鼠。与亲代菌株李斯特菌和LC16mO相比，LC16m8在三种小鼠模型中的毒力极低。这些结果进一步证明LC16m8是世界上最安全的具有复制能力的天花疫苗之一，可考虑用于免疫缺陷患者。
相似文献
1
Safety of attenuated smallpox vaccine LC16m8 in immunodeficient mice.减毒天花疫苗LC16m8在免疫缺陷小鼠中的安全性
Clin Vaccine Immunol. 2014 Sep;21(9):1261-6. doi: 10.1128/CVI.00199-14. Epub 2014 Jul 2.
2
Vaccinia virus strain LC16m8 defective in the B5R gene keeps strong protection comparable to its parental strain Lister in immunodeficient mice.在B5R基因上存在缺陷的痘苗病毒株LC16m8，在免疫缺陷小鼠中保持着与亲代菌株李斯特菌相当的强大保护作用。
Vaccine. 2015 Nov 9;33(45):6112-9. doi: 10.1016/j.vaccine.2015.07.076. Epub 2015 Aug 1.
3
Recent advances in the study of live attenuated cell-cultured smallpox vaccine LC16m8.减毒活细胞培养天花疫苗LC16m8的研究新进展。
Vaccine. 2015 Nov 9;33(45):6106-11. doi: 10.1016/j.vaccine.2015.07.111. Epub 2015 Aug 28.
4
Freeze-dried live attenuated smallpox vaccine prepared in cell culture "LC16-KAKETSUKEN": Post-marketing surveillance study on safety and efficacy compliant with Good Clinical Practice.细胞培养制备的冻干减毒活天花疫苗“LC16 - 家蚕研”：符合良好临床实践的上市后安全性和有效性监测研究
Vaccine. 2015 Nov 9;33(45):6120-7. doi: 10.1016/j.vaccine.2015.09.067. Epub 2015 Oct 9.
5
Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.LC16m8，一种减毒天花疫苗在从未接种过牛痘的成年人中的安全性和免疫原性。
J Infect Dis. 2011 Nov;204(9):1395-402. doi: 10.1093/infdis/jir527. Epub 2011 Sep 15.
6
Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8.由高度减毒的痘苗病毒LC16m8构建的基因稳定且完全有效的天花疫苗株。
Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4152-7. doi: 10.1073/pnas.0406671102. Epub 2005 Mar 7.
7
LC16m8: an attenuated smallpox vaccine.LC16m8：一种减毒天花疫苗。
Vaccine. 2006 Nov 17;24(47-48):7009-22. doi: 10.1016/j.vaccine.2006.03.087. Epub 2006 Apr 21.
8
Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8.对减毒组织培养天花疫苗LC16m8的临床和免疫反应。
JAMA. 2009 Mar 11;301(10):1025-33. doi: 10.1001/jama.2009.289.
9
An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection.一种减毒的LC16m8天花疫苗：全基因组序列分析及免疫保护诱导
J Virol. 2005 Sep;79(18):11873-91. doi: 10.1128/JVI.79.18.11873-11891.2005.
10
A Single Vaccination of Nonhuman Primates with Highly Attenuated Smallpox Vaccine, LC16m8, Provides Long-term Protection against Monkeypox.用高度减毒的天花疫苗LC16m8对非人灵长类动物进行单次接种，可提供针对猴痘的长期保护。
Jpn J Infect Dis. 2017 Jul 24;70(4):408-415. doi: 10.7883/yoken.JJID.2016.417. Epub 2016 Dec 22.
引用本文的文献
1
Development of a Broad-Spectrum Pan-Mpox Vaccine via Immunoinformatic Approaches.通过免疫信息学方法开发广谱泛痘疫苗。
Int J Mol Sci. 2025 Jul 25;26(15):7210. doi: 10.3390/ijms26157210.
2
An open-label, non-randomized study investigating the safety and efficacy of smallpox vaccine, LC16, as post-exposure prophylaxis for mpox.一项关于天花疫苗 LC16 作为猴痘暴露后预防的安全性和有效性的开放标签、非随机研究。
Hum Vaccin Immunother. 2023 Aug 1;19(2):2242219. doi: 10.1080/21645515.2023.2242219.
3
Monkeypox: Clinical Issues of Concern.猴痘：值得关注的临床问题
J Transl Int Med. 2023 Jan 13;10(4):297-299. doi: 10.2478/jtim-2022-0038. eCollection 2022 Dec.
4
Monkeypox (Mpox) vaccines and their side effects: the other side of the coin.猴痘疫苗及其副作用：硬币的另一面。
Int J Surg. 2023 Feb 1;109(2):215-217. doi: 10.1097/JS9.0000000000000142.
5
Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution.应对未来病毒进化的新一代冠状病毒疫苗进展
Vaccines (Basel). 2022 Nov 29;10(12):2035. doi: 10.3390/vaccines10122035.
6
Immunoinformatics-Aided Design of a Peptide Based Multiepitope Vaccine Targeting Glycoproteins and Membrane Proteins against Monkeypox Virus.基于免疫信息学的猴痘病毒糖蛋白和膜蛋白多表位肽疫苗设计。
Viruses. 2022 Oct 27;14(11):2374. doi: 10.3390/v14112374.
7
Monkeypox: epidemiology, pathogenesis, treatment and prevention.猴痘：流行病学、发病机制、治疗和预防。
Signal Transduct Target Ther. 2022 Nov 2;7(1):373. doi: 10.1038/s41392-022-01215-4.
8
Vaccinia Virus Expressing Interferon Regulatory Factor 3 Induces Higher Protective Immune Responses against Lethal Poxvirus Challenge in Atopic Organism.牛痘病毒表达干扰素调节因子 3 可诱导特应性生物体对致死性痘病毒攻击产生更高的保护免疫应答。
Viruses. 2021 Oct 3;13(10):1986. doi: 10.3390/v13101986.
9
A Critical Analysis of the Scientific and Commercial Rationales for the Synthesis of Horsepox Virus.对马痘病毒合成的科学与商业原理的批判性分析
mSphere. 2018 Mar 7;3(2). doi: 10.1128/mSphere.00040-18. eCollection 2018 Mar-Apr.
10
Construction and characterization of bacterial artificial chromosomes harboring the full-length genome of a highly attenuated vaccinia virus LC16m8.携带高度减毒痘苗病毒LC16m8全长基因组的细菌人工染色体的构建与鉴定
PLoS One. 2018 Feb 23;13(2):e0192725. doi: 10.1371/journal.pone.0192725. eCollection 2018.
本文引用的文献
1
Meeting of the Strategic Advisory Group of Experts on immunization, November 2013 -- conclusions and recommendations.免疫战略咨询专家组会议，2013年11月——结论与建议
Wkly Epidemiol Rec. 2014 Jan 3;89(1):1-19.
2
Smallpox vaccine safety is dependent on T cells and not B cells.天花疫苗的安全性依赖于 T 细胞，而不是 B 细胞。
J Infect Dis. 2011 Apr 15;203(8):1043-53. doi: 10.1093/infdis/jiq162.
3
A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.一项评估第三代天花疫苗候选药物 IMVAMUNE 免疫原性和安全性的随机、双盲、剂量探索性 II 期研究。
Vaccine. 2010 Feb 3;28(5):1209-16. doi: 10.1016/j.vaccine.2009.11.030. Epub 2009 Nov 25.
4
Induction of natural killer cell responses by ectromelia virus controls infection.埃可病毒诱导自然杀伤细胞反应以控制感染。
J Virol. 2007 Apr;81(8):4070-9. doi: 10.1128/JVI.02061-06. Epub 2007 Feb 7.
5
LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox.LC16m8是一种高度减毒的痘苗病毒疫苗，缺乏膜蛋白B5R的表达，可保护猴子免受猴痘感染。
J Virol. 2006 Jun;80(11):5179-88. doi: 10.1128/JVI.02642-05.
6
An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection.一种减毒的LC16m8天花疫苗：全基因组序列分析及免疫保护诱导
J Virol. 2005 Sep;79(18):11873-91. doi: 10.1128/JVI.79.18.11873-11891.2005.
7
Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8.由高度减毒的痘苗病毒LC16m8构建的基因稳定且完全有效的天花疫苗株。
Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4152-7. doi: 10.1073/pnas.0406671102. Epub 2005 Mar 7.
8
Biodefense. Smallpox vaccines: looking beyond the next generation.生物防御。天花疫苗：展望下一代之后。
Science. 2004 May 7;304(5672):809. doi: 10.1126/science.304.5672.809a.
9
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.一种高度减毒的痘苗病毒载体天花疫苗的免疫原性及对猴痘的防护作用
Nature. 2004 Mar 11;428(6979):182-5. doi: 10.1038/nature02331.
10
Myocarditis: the unexpected return of smallpox vaccine adverse events.心肌炎：天花疫苗不良事件的意外重现。
Lancet. 2003 Oct 25;362(9393):1345-6. doi: 10.1016/S0140-6736(03)14674-0.
Zotero 插件